BioSpace News Archive

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of miglustat, the enzyme stabilizer component of AT-GAA.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that transverse tissue barriers to selectively target activated cells in regions of inflammation, today announced two preclinical data sets demonstrating the efficacy of its anti-angiogenic precision nanomedicine, D-4517.2.

ELEVAI LABS, INC. is pleased to report a stem cell exosome research partnership with Dr. Stanislav Sokolenko’s Lab at Dalhousie University and a non-repayable Grant from the Mitacs Accelerate Grants Program.

AdvaMed, the MedTech Association, released the findings of a new national poll on radiation therapy and cancer treatment revealing broad support for greater federal investment in the proven cancer treatment of radiation therapy, to bring down costs and expand access for patients.

Blue Water Biotech, Inc., a biotechnology company spanning multiple sectors, announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer.

Tevogen Bio is pleased to announce that its Chief Scientific Officer, Dr. Neal Flomenberg, will be presenting at the Long COVID, Inflammation, and Cancer Conclave, hosted by the No One Left Alone (NOLA) Foundation on May 12, 2023, in Charlotte, North Carolina.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2023 on Wednesday, May 3 at 9 a.m., ET.

CND Life Sciences, a medical technology company pioneering the development of cutaneous neurodiagnostics, announced topline results from its landmark Synuclein-One Study sponsored by the National Institutes of Health.

The Galactosemia Foundation urges the U.S Food and Drug Administration (FDA) to incorporate the experiences and perspectives of people living with galactosemia and their caregivers in the agency’s review of govorestat (AT-007), the potential first-ever treatment for this rare genetic disease that can be life-threatening for newborns and cause severe lifelong complications.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized inOLINGUITO, the pivotal Phase 3 program of filgotinib inAxSpA.Topline results are expected in H2 2025.